Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.
Eli Lilly has reported second-quarter earnings and revenue that exceeded estimates, driven by strong demand for its weight loss drug Zepbound and diabetes treatment Mounjaro. The company's worldwide revenue for Mounjaro rose 91% to $9.94 billion for the quarter, with U.S. sales reaching $4.8 billion.
As a result, Eli Lilly has raised its full-year sales outlook. The company now expects 2026 revenue to be between $85 billion and $87 billion, up from its previous guidance of $82 billion to $85 billion.
The company's adjusted profit is now projected to be between $35.50 and $36.50 per share. Shares of Eli Lilly rose more than 5% in premarket trading following the announcement, according to CNBC.
Brief written by urgent.news from CNBC World, CNBC — 2 reports on this story. Machine-written — it may contain errors, so check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
